Pricing Log in Create free account

Clearside Biomedical, Inc. (CLSDQ) vs Matinas Biopharma Holdings, Inc. (MTNB)

Clearside Biomedical, Inc. and Matinas Biopharma Holdings, Inc. are both Biotechnology companies. Matinas Biopharma Holdings, Inc. is the larger, with a market value of $2.4M against $2.2M — 1.1× the size. Matinas Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 2,139.4% against −56.8%. Matinas Biopharma Holdings, Inc. has the higher net margin (0.00% vs −780.9%) and the lower return on invested capital (−419.3% vs 0.00%). Across the 17 metrics below, Matinas Biopharma Holdings, Inc. leads on 11 and Clearside Biomedical, Inc. on 6.

Valuation

Metric CLSDQ MTNB Biotechnology median
P/E n/m n/m 8.50
P/S 0.39 0.24 9.71
P/B n/m 0.56 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.18 n/m 0.64
EV/Sales (1.24) 0.05 9.21
Earnings yield (2,075.24%) (348.48%) (33.15%)
Free cash flow yield (1,661.90%) (602.45%) (25.50%)

Profitability

Metric CLSDQ MTNB Biotechnology median
Gross margin 92.55% 0.00% 65.16%
Operating margin (689.76%) 0.00% 0.00%
Net margin (780.93%) 0.00% 0.00%
Free cash flow margin (653.23%) 0.00% 0.00%
Return on equity 58.59% (154.28%) (56.36%)
Return on assets (127.43%) (98.53%) (48.04%)
Return on invested capital 0.00% (419.27%) 0.00%

Growth

Metric CLSDQ MTNB Biotechnology median
Revenue growth (TTM) (56.78%) 2,139.41% 6.02%
EPS growth (last fiscal year) 11.32% 62.08% 30.26%
Revenue growth, 5-year CAGR (5.20%) 55.69% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLSDQ MTNB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.98 0.85 4.72
Net debt to EBITDA 0.69 0.62 0.96

Dividend

Metric CLSDQ MTNB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLSDQ MTNB Biotechnology median
Market cap 2.15m 2.37m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack